Expertise in
1
conditions

Dr. Marka R. Crittenden

Radiation Oncology
The Oregon Clinic Radiation Oncology
4805 NE Glisan St, 
Portland, OR 
Accepting New Patients
Referral may be required
Expertise in
1
conditions
The Oregon Clinic Radiation Oncology
4805 NE Glisan St, 
Portland, OR 

Overview

Marka Crittenden is a Radiation Oncologist practicing medicine in Portland, Oregon.

Dr. Crittenden is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Cancer, Glioma, and Lung Cancer.

She is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 5 clinical trials. Dr. Crittenden is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in OR

Hospital Affiliations

Providence Portland Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

The Oregon Clinic Radiation Oncology
4805 NE Glisan St, Portland, OR 97213
Other Locations
4805 Northeast Glisan Street, Garden Level, Portland, OR 97213

Additional Areas of Focus

Dr. Crittenden has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Radiation, Biological
Study Drug: High Dose IL-2
Study Phase: Phase 2
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: LY2157299, Capecitabine, Fluorouracil
Study Phase: Phase 2
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

73 Total Publications

Fluorescence tracking CD8 T cells from tumor-draining lymph nodes to irradiated tumors and their activation in the tumor environment.
Fluorescence tracking CD8 T cells from tumor-draining lymph nodes to irradiated tumors and their activation in the tumor environment.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 09, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Arthur Y. Hung
Radiation Oncology
Expertise in
21
conditions
Dr. Arthur Y. Hung
Radiation Oncology
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (4.1 miles away)
503-494-8756
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arthur Hung is a Radiation Oncologist practicing medicine in Portland, Oregon. Dr. Hung is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, Prostatectomy, and Orchiectomy. Dr. Hung is currently accepting new patients.

Expertise in
9
conditions
Dr. Timur E. Mitin
Radiation Oncology
Expertise in
9
conditions
Dr. Timur E. Mitin
Radiation Oncology
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (4.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timur Mitin is a Radiation Oncologist practicing medicine in Portland, Oregon. Dr. Mitin is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Small Cell Lung Cancer (SCLC), Familial Prostate Cancer, Prostatectomy, and Orchiectomy. Dr. Mitin is currently accepting new patients.

Expertise in
16
conditions
Dr. Stephen B. Bader
Radiation Oncology
Expertise in
16
conditions
Dr. Stephen B. Bader
Radiation Oncology
Referral may be required
4805 Ne Glisan St, Garden Level, 
Portland, OR 
 (0.1 miles away)
503-215-6029
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Bader is a Radiation Oncologist practicing medicine in Portland, Oregon. Dr. Bader is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Pleuropulmonary Blastoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Bader is currently accepting new patients.

Frequently Asked Questions about Dr. Marka R. Crittenden

How do I make an appointment with Dr. Marka R. Crittenden?

You can book an appointment with Dr. Marka R. Crittenden by calling their office at 503-215-6029. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marka R. Crittenden a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marka R. Crittenden is classified as an Advanced expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marka R. Crittenden specialize in?

While Dr. Marka R. Crittenden is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Cancer, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Marka R. Crittenden participate in research or clinical trials?

Yes. Dr. Marka R. Crittenden has published 73 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Marka R. Crittenden's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marka R. Crittenden accept my insurance?

Dr. Marka R. Crittenden accepts most major insurance plans, including Aetna and BridgeSpan. We recommend calling the office directly at 503-215-6029 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crittenden's expertise for a condition
ConditionClose
      View All 33 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile